174 related articles for article (PubMed ID: 25896346)
21. [Serum myostatin levels and malnutrition in patients with chronic obstructive pulmonary disease].
Ju CR; Chen RC
Zhonghua Nei Ke Za Zhi; 2011 Jun; 50(6):465-8. PubMed ID: 21781527
[TBL] [Abstract][Full Text] [Related]
22. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Fahrleitner-Pammer A; Amrein K; Pietschmann P; Haschka J; Dinu S; Kapiotis S; Resch H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E311-9. PubMed ID: 24203063
[TBL] [Abstract][Full Text] [Related]
23. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
van Lierop AH; Witteveen JE; Hamdy NA; Papapoulos SE
Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
[TBL] [Abstract][Full Text] [Related]
24. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease.
Ju CR; Chen RC
Respir Med; 2012 Jan; 106(1):102-8. PubMed ID: 21840694
[TBL] [Abstract][Full Text] [Related]
25. Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury.
Wang TD; Wang YH; Huang TS; Su TC; Pan SL; Chen SY
J Formos Med Assoc; 2007 Nov; 106(11):919-28. PubMed ID: 18063513
[TBL] [Abstract][Full Text] [Related]
26. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study.
Ardawi MS; Rouzi AA; Qari MH
J Clin Endocrinol Metab; 2012 Oct; 97(10):3691-9. PubMed ID: 22865898
[TBL] [Abstract][Full Text] [Related]
27. Chronic activity-based therapy does not improve body composition, insulin-like growth factor-I, adiponectin, or myostatin in persons with spinal cord injury.
Astorino TA; Harness ET; Witzke KA
J Spinal Cord Med; 2015 Sep; 38(5):615-25. PubMed ID: 25130192
[TBL] [Abstract][Full Text] [Related]
28. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients.
Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E
Nephron; 2016; 132(3):181-90. PubMed ID: 26890570
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
[TBL] [Abstract][Full Text] [Related]
30. Serum sclerostin in alcoholics: a pilot study.
González-Reimers E; Martín-González C; de la Vega-Prieto MJ; Pelazas-González R; Fernández-Rodríguez C; López-Prieto J; Alvisa-Negrín J; Santolaria-Fernández F
Alcohol Alcohol; 2013; 48(3):278-82. PubMed ID: 23296214
[TBL] [Abstract][Full Text] [Related]
31. Impact of specific symptoms of spasticity on voluntary lower limb muscle function, gait and daily activities during subacute and chronic spinal cord injury.
Bravo-Esteban E; Taylor J; Abián-Vicén J; Albu S; Simón-Martínez C; Torricelli D; Gómez-Soriano J
NeuroRehabilitation; 2013; 33(4):531-43. PubMed ID: 24018366
[TBL] [Abstract][Full Text] [Related]
32. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
[TBL] [Abstract][Full Text] [Related]
33. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
34. Circulating sclerostin in children and young adults with heritable bone disorders.
Palomo T; Glorieux FH; Rauch F
J Clin Endocrinol Metab; 2014 May; 99(5):E920-5. PubMed ID: 24512494
[TBL] [Abstract][Full Text] [Related]
35. Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients.
Léger B; Senese R; Al-Khodairy AW; Dériaz O; Gobelet C; Giacobino JP; Russell AP
Muscle Nerve; 2009 Jul; 40(1):69-78. PubMed ID: 19533653
[TBL] [Abstract][Full Text] [Related]
36. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
[TBL] [Abstract][Full Text] [Related]
37. The relation between serum MDA and cystatin C levels in chronic spinal cord injury patients.
Koçak H; Oner-Iyidoğan Y; Gürdöl F; Koçak T; Esin D
Clin Biochem; 2005 Nov; 38(11):1034-7. PubMed ID: 16154555
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Value of Serum Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings in Severity Assessment of Human Traumatic Spinal Cord Injury.
Ahadi R; Khodagholi F; Daneshi A; Vafaei A; Mafi AA; Jorjani M
Spine (Phila Pa 1976); 2015 Jul; 40(14):E823-30. PubMed ID: 25341992
[TBL] [Abstract][Full Text] [Related]
39. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
van Lierop AH; Hamdy NA; van Egmond ME; Bakker E; Dikkers FG; Papapoulos SE
J Bone Miner Res; 2013 Apr; 28(4):848-54. PubMed ID: 23074140
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of testosterone deficiency after spinal cord injury.
Durga A; Sepahpanah F; Regozzi M; Hastings J; Crane DA
PM R; 2011 Oct; 3(10):929-32. PubMed ID: 22024324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
